TREATMENT ACCESS
When Cancer Treatment Becomes an International Question
A patient can have excellent physicians, strong insurance coverage and access to leading cancer centers — and still discover that a specific treatment is not yet available in their healthcare system.
The relevant question is not whether one country has “better cancer care.” It is whether a specific treatment capability exists, whether the evidence is credible, whether it fits the patient, and whether it can be accessed responsibly.
Why Treatment Availability Differs Between Countries
Research activity, regulatory approval, commercial launch, clinical-trial enrollment and insurance coverage are five different things. A treatment can be true on one of these dimensions in one country and not yet true on that same dimension in another.
A therapy can be under active study in one country, approved in another, commercially available in one health system, or offered through a trial that exists elsewhere but is no longer accepting new participants. None of these states by itself means the treatment is appropriate for a particular patient.
01
Research
A therapy is being studied in clinical trials.
02
Regulatory Approval
A regulator has reviewed the evidence and approved the therapy for a defined indication.
03
Commercial Availability
The approved therapy can actually be obtained through the health system, not only through a trial.
04
Patient-Specific Access
The specific patient’s diagnosis, biomarkers, prior treatment and fitness determine whether the therapy is actually relevant to them.
China’s Drug-Development Landscape Has Changed
Patients and physicians often carry an assumption formed years ago: that meaningful cancer-drug innovation happens in the United States and Europe first, and everywhere else later. That assumption is now frequently outdated, and the shift is documented in the same peer-reviewed and industry sources used to track drug development anywhere else.
~30%
Share of the global pharmaceutical pipeline now attributed to China, making it the world’s second-largest biopharmaceutical R&D hub.
84 vs. 85
Oncology novel active substances launched in China versus the United States, 2020–2024.
45
Of China’s 2020–2024 oncology launches, the number that had not yet launched in any other market at the time of the report.
China is not the right treatment destination for every patient. But country of origin is increasingly an unreliable shortcut for judging where meaningful pharmaceutical innovation is occurring.
Excellent Healthcare Does Not Guarantee Access to Every Treatment
Insurance can pay for treatments that are available within its covered health system. It cannot itself create commercial access to a therapy that is not yet available in that market.
A leading hospital can provide world-class treatment and clinical trials. It still operates within the therapies, regulatory approvals, open studies and access mechanisms actually available to it — not therapies that exist only in another health system.
This is why an international treatment question can arise even for a well-insured patient already receiving excellent local care. It is not a failure of that care. It is a gap in treatment-specific availability.
A Current Example: CLDN18.2-Directed Treatment
This is one concrete, currently-verifiable example of how availability can diverge. It is not proof that every patient should consider China — only a case study of how the four-step pattern above plays out in practice.
UNITED STATES
In October 2024, the FDA approved zolbetuximab (VYLOY) for first-line treatment of CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, given with chemotherapy.
The related North American CT041 trial of the same CLDN18.2 target (NCT04404595) is independently verified as active, not recruiting — the study continues to follow already-enrolled patients but is not currently accepting new participants. A trial can remain active for follow-up while closed to new enrollment; that alone does not mean every treatment or trial option has ended.
CHINA
In 2026, Chinese regulators approved satri-cel (satricabtagene autoleucel) — the first CAR-T therapy approved anywhere for the treatment of a solid tumor — for CLDN18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma after failure of at least two prior systemic treatment lines.
This is a later-line indication — for patients whose disease has progressed after at least two prior systemic treatments — not a first-line alternative to VYLOY.
These are two different treatments, for two different points in a patient’s treatment line, approved through two different regulatory systems. Neither fact alone tells a specific patient what to do next.
Does This Mean a Patient Should Travel to China?
No.
China becomes relevant only if the specific treatment capability is relevant to that patient’s own case.
01
Current disease state
02
Available local standard treatments
03
Currently feasible clinical trials
04
Biomarker / indication fit
05
Current clinical fitness
06
Formal overseas clinical review, if still relevant
Licensed treating physicians and institutions make medical decisions. This sequence does not replace that judgment — it explains when an overseas review becomes a reasonable question to ask.
What Should Be Understood Before Anyone Travels?
Can the case be reviewed before travel?
What records are required?
Does the treatment indication fit the case?
What local alternatives remain?
What would the treatment episode include?
What is known about timing and total episode economics?
What are the major exceptions and complication costs?
How will treatment records return to the home oncology team?
These are exactly the questions a structured intake and clinical review are designed to answer before any travel decision is made.
Current Vialen Example
For selected advanced gastric / GEJ cases, Vialen currently maintains a treatment-specific pathway around CLDN18.2-directed CAR-T review.
If the case is already close to this treatment question, the next step is a structured review — not a travel decision.